Attached files

file filename
EX-99.1 - EX-99.1 - Bausch Health Companies Inc.a10-4452_2ex99d1.htm

 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): February 25, 2010

 

BIOVAIL CORPORATION

(Exact name of registrant as specified in its charter)

 

Canada

 

001-14956

 

Not Applicable

(State or other jurisdiction

 

(Commission File Number)

 

(IRS Employer

of incorporation)

 

 

 

Identification Number)

 

7150 Mississauga Road

Mississauga, Ontario

Canada

 

L5N 8M5

(Address of principal executive offices)

 

(Zip Code)

 

Registrant’s telephone number, including area code: (905) 286-3000

 

(Former name or former address, if changed since last report.)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

o            Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

o            Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

o            Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

o            Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 



 

ITEM 2.02           RESULTS OF OPERATIONS AND FINANCIAL CONDITION

 

The following information is furnished pursuant to Item 2.02, “Results of Operations and Financial Condition.”

 

On February 25, 2010, Biovail Corporation (the “Company”) issued a press release setting forth its financial results for its fourth quarter and year ended December 31, 2009. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K. The Company does not intend for this Item 2.02 or Exhibit 99.1 to be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or to be incorporated by reference into filings under the Securities Act of 1933, as amended.

 

ITEM 9.01           FINANCIAL STATEMENTS AND EXHIBITS

 

(d)  Exhibit

 

99.1

Press release of Biovail Corporation, issued February 25, 2010, and furnished pursuant to Item 2.02, “Results of Operations and Financial Condition.”

 

2



 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

BIOVAIL CORPORATION

 

 

 

 

By:

/s/ Jennifer Tindale

 

Name:

Jennifer Tindale

 

Title:

VP, Associate General Counsel

 

 

and Corporate Secretary

 

 

 

Date: February 25, 2010

 

 

 

3



 

EXHIBIT INDEX

 

Exhibit

 

 

Number

 

Description

 

 

 

99.1

 

Press release of Biovail Corporation, issued February 25, 2010, and furnished pursuant to Item 2.02, “Results of Operations and Financial Condition.”

 

4